Ipsen and GENFIT Announce Positive Results from Phase III EL

Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE® trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease

Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE® trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease

tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Saclay , France General , France , Paris , United States , Canada , Shanghai , China , Cambridge , Cambridgeshire , United Kingdom , Switzerland , American , French , Nicolas Bogler , Ipsen Euronext , Pascal Prigent , Jean Christophe Marcoux , Amy Wolf , Ioana Piscociu , Anna Gibbins , Stephanie Boyer , Howard Mayer , Development For Ipsen , Uncertainties Of The Company , Corporate Affairs , Head Of Corporate Brand Strategy Communications Tel , Exchange Commission , Global Head Of Franchise Communications , Head Of Research , Drug Administration , Euronext , European Medicines Agency , Nasdaq , Positive Results , Executive Vice President , Chief Executive Officer , Breakthrough Therapy , Rare Disease , Sponsored Leveli American Depositary Receipt , Nasdaq Global Select Market , French Autorit , Des March , Universal Registration Document , Private Securities Litigation Reform Act , Registration Document , Vice President , Investor Relations , Investor Relations Manager , Global Head , Franchise Communications , Senior Manager Global Media Relations , Corporate Brand Strategy , Christophe Marcoux , Chief Corporate Affairs Officer , Orphanetj Rare , Transplantation Hepatology ,